Literature DB >> 22052334

Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls.

Tal Shahar1, Zvi Ram, Andrew A Kanner.   

Abstract

Convection-enhanced delivery (CED) of compounds into brain tumors reportedly circumvents the blood brain barrier. CED intends to increase drug delivery to malignant cells, reaching high local therapeutic concentration and decreasing or eliminating systemic side effects. Clinical experience and published data on catheter placement (CP) surgery are scarce. We propose practical and technical guidelines for planning CED based on our experience. We retrospectively analyzed the medical charts and relevant neuroimages of 25 patients following the insertion of 64 CED catheters. The patients were enrolled in at least one of four clinical trials using CED for treating recurrent glioblastoma multiforme in our institution between 2003-2006. Intra- and postoperative complications related to CP surgery and the difficulties and pitfalls of planning were evaluated. There were 29 CP surgeries. Forty-four peritumoral brain tissue catheters were inserted in 16 CP surgeries following tumor resection in 16 patients, and 20 catheters were placed into the tumor in 13 procedures in 10 patients. The lesions were in or near eloquent brain tissue areas in 13 of all CP surgeries. Complications included increased edema (31%), infection (6.9%), bleeding (6.9%) and seizures (13.8%). Significant neurological deterioration occurred in 4 patients (13.8%). Difficulties in adhering to CP surgery guidelines included lesion site (superficial, mesial temporal lobe, proximity to CSF spaces), proximity to eloquent cortical areas, tissue density that interfered with the trajectory, and technical limitations of stereotactic instruments. CED procedures for high-grade gliomas may be associated with surgical morbidity. Adherence to guidelines might be difficult because of lesion site and complicated by brain and tumor tissue characteristics. This should be considered while planning clinical trials that use convection-based technology.

Entities:  

Mesh:

Year:  2011        PMID: 22052334     DOI: 10.1007/s11060-011-0751-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Direct delivery of medication into a brain tumor through multiple chronically implanted catheters.

Authors:  G Bouvier; R D Penn; J S Kroin; R Beique; M J Guerard
Journal:  Neurosurgery       Date:  1987-02       Impact factor: 4.654

2.  High-flow microinfusion: tissue penetration and pharmacodynamics.

Authors:  P F Morrison; D W Laske; H Bobo; E H Oldfield; R L Dedrick
Journal:  Am J Physiol       Date:  1994-01

3.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

4.  Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Authors:  John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

5.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

Authors:  D W Laske; R J Youle; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

6.  Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.

Authors:  Jeffrey W Degen; Stuart Walbridge; Alexander O Vortmeyer; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2003-11       Impact factor: 5.115

7.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

Authors:  Zvi Lidar; Yael Mardor; Tali Jonas; Raphael Pfeffer; Meir Faibel; Dvora Nass; Moshe Hadani; Zvi Ram
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

Review 8.  Local treatment of brain tumors with targeted chimera cytotoxic proteins.

Authors:  Waldemar Debinski
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 9.  Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

Review 10.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more
  10 in total

1.  Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging.

Authors:  Guifa Xi; Veena Rajaram; Babara Mania-Farnell; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  Childs Nerv Syst       Date:  2012-01-27       Impact factor: 1.475

Review 2.  Convection-enhanced delivery for the treatment of glioblastoma.

Authors:  Michael A Vogelbaum; Manish K Aghi
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

3.  MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.

Authors:  Kelsie F Timbie; Umara Afzal; Abhijit Date; Clark Zhang; Ji Song; G Wilson Miller; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  J Control Release       Date:  2017-03-11       Impact factor: 9.776

Review 4.  Convection-enhanced delivery for high-grade glioma.

Authors:  Jennifer H Kang; Annick Desjardins
Journal:  Neurooncol Pract       Date:  2021-11-20

Review 5.  Drug and gene delivery across the blood-brain barrier with focused ultrasound.

Authors:  Kelsie F Timbie; Brian P Mead; Richard J Price
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

Review 6.  Which drug or drug delivery system can change clinical practice for brain tumor therapy?

Authors:  Tali Siegal
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300

Review 7.  Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.

Authors:  Arman Jahangiri; Aaron T Chin; Patrick M Flanigan; Rebecca Chen; Krystof Bankiewicz; Manish K Aghi
Journal:  J Neurosurg       Date:  2016-04-01       Impact factor: 5.115

8.  A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.

Authors:  Vanessa Bellat; Yago Alcaina; Ching-Hsuan Tung; Richard Ting; Adam O Michel; Mark Souweidane; Benedict Law
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

9.  Convection-enhanced drug delivery for gliomas.

Authors:  Andrew T Healy; Michael A Vogelbaum
Journal:  Surg Neurol Int       Date:  2015-02-13

Review 10.  Immunotherapy for Pediatric Brain Tumors.

Authors:  Elias J Sayour; Duane A Mitchell
Journal:  Brain Sci       Date:  2017-10-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.